FDAnews Drug Daily Bulletin
Pharmaceuticals / Regulatory Affairs

Jury Sides With J&J, Bayer Over Xarelto Drug Liability Claims

Aug. 31, 2017
A A

Johnson & Johnson and Bayer scored another win in the myriad of cases brought by patients claiming the drugmakers’ prescription blood thinner Xarelto caused internal bleeding.

A jury in the most recently decided case, assigned to the U.S. District Court for the Eastern District of Louisiana, dismissed liability claims on Aug. 18, finding the plaintiff had failed to prove her failure-to-warn claim. The case is the third of 40 “bellwether” cases in the action, with the defendants prevailing in all three.

Xarelto, first approved by the FDA in 2011, is primarily used to reduce the risk of stroke and systemic embolism, as well as to treat deep vein thrombosis and pulmonary embolism.

View today's stories